155 related articles for article (PubMed ID: 31851160)
1. Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia.
Kasner MT
Clin Adv Hematol Oncol; 2019 Nov; 17(11):604-606. PubMed ID: 31851160
[No Abstract] [Full Text] [Related]
2. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
Krauss AC; Gao X; Li L; Manning ML; Patel P; Fu W; Janoria KG; Gieser G; Bateman DA; Przepiorka D; Shen YL; Shord SS; Sheth CM; Banerjee A; Liu J; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2019 May; 25(9):2685-2690. PubMed ID: 30541745
[TBL] [Abstract][Full Text] [Related]
3. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Salhotra A; Aribi A; Ngo D; Zhang J; Sandhu K; Al-Malki M; Ali H; Koller P; Arslan S; Budde E; Khaled S; Dadwal S; Snyder DS; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
Am J Hematol; 2021 Jun; 96(6):E196-E200. PubMed ID: 33719090
[No Abstract] [Full Text] [Related]
4. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Tzogani K; Penttilä K; Lapveteläinen T; Hemmings R; Koenig J; Freire J; Márcia S; Cole S; Coppola P; Flores B; Barbachano Y; Roige SD; Pignatti F
Oncologist; 2020 Sep; 25(9):e1414-e1420. PubMed ID: 32282100
[TBL] [Abstract][Full Text] [Related]
5. Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia.
Blair HA
Drugs; 2018 Dec; 78(18):1903-1910. PubMed ID: 30511323
[TBL] [Abstract][Full Text] [Related]
6. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
7. In brief: Two new drugs for AML.
Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
[No Abstract] [Full Text] [Related]
8. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
[TBL] [Abstract][Full Text] [Related]
9. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract][Full Text] [Related]
10. Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.
Howell G; Oliai C; Schiller G
Anticancer Res; 2018 Dec; 38(12):6927-6930. PubMed ID: 30504411
[TBL] [Abstract][Full Text] [Related]
11. Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia.
Nowrousian MR; Pfeiffer R; Schaefer UW; Osieka R; Niederle N; Anders C; Schmidt CG
Haematol Blood Transfus; 1987; 30():352-5. PubMed ID: 3305206
[No Abstract] [Full Text] [Related]
12. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
[TBL] [Abstract][Full Text] [Related]
13. Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia.
Tefferi A; Letendre L
J Clin Oncol; 2012 Jul; 30(20):2425-8. PubMed ID: 22529263
[No Abstract] [Full Text] [Related]
14. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
[TBL] [Abstract][Full Text] [Related]
15. Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes.
Triesel K; Chiang T; Seabury R; Miller C
J Oncol Pharm Pract; 2021 Sep; 27(6):1539-1541. PubMed ID: 33307969
[TBL] [Abstract][Full Text] [Related]
16. Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
Othus M; Estey EH; Garcia-Manero G; Wood BL; Stirewalt DL; Godwin JE; Weick JK; Anderson JE; Appelbaum FR; Erba HP; Walter RB
Leukemia; 2019 Feb; 33(2):554-558. PubMed ID: 30315233
[No Abstract] [Full Text] [Related]
17. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Cortes J; Estey E; O'Brien S; Giles F; Shen Y; Koller C; Beran M; Thomas D; Keating M; Kantarjian H
Cancer; 2001 Jul; 92(1):7-14. PubMed ID: 11443603
[TBL] [Abstract][Full Text] [Related]
18. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
19. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
[TBL] [Abstract][Full Text] [Related]
20. Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.
Marty M; Lepage E; Guy H; Bordessoule D; Desablens B; Harousseau JL; Guilhot F; Leverger G; Schaison G; Boiron M
Haematol Blood Transfus; 1987; 30():50-6. PubMed ID: 3305217
[No Abstract] [Full Text] [Related]
[Next] [New Search]